Dr. James Brooks's group's interest is in developing diagnostic and prognostic markers for urological diseases. Their work spans discovery, measurement methodologies, and clinical validation of candidate biomarkers. They have primarily used genomic and proteomic approaches for biomarker discovery. While their primary focus has been in prostate cancer, we have also worked in kidney cancer and other malignancies.